Ver­tex wa­gers $70M on Kymera and its new fas­ci­na­tion with pro­tein degra­da­tion

One of Ver­tex’s key promis­es to in­vestors and pa­tients has been that it will de­ploy its suc­cess in cys­tic fi­bro­sis — which fi­nal­ly turned the 30-year-old biotech in­to a prof­itable busi­ness three years ago — to fund more R&D projects with in­no­v­a­tive tech­nolo­gies. It has pro­pelled them to dive in­to gene edit­ing, team up with CRISPR Ther­a­peu­tics to test what could be a pi­o­neer­ing treat­ment for sick­le cell dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.